RA
UTHR icon

Rational Advisors’s United Therapeutics UTHR Stock Holding History

Rational Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-59
Closed -$6K – 582
2020
Q3 		$6K Buy
59
+40
+211% +$4.39K ﹤0.01% 356
2020
Q2 		$2K Buy
+19
New +$2.14K ﹤0.01% 488
2020
Q1 		– Sell
-99
Closed -$9K – 505
2019
Q4 		$9K Hold
99
– – ﹤0.01% 462
2019
Q3 		$8K Sell
99
-144
-59% -$11.6K ﹤0.01% 509
2019
Q2 		$19K Buy
243
+239
+5,975% +$22.3K 0.01% 449
2019
Q1 		$0 Sell
4
-3
-43% -$350 ﹤0.01% 569
2018
Q4 		$1K Hold
7
– – ﹤0.01% 510
2018
Q3 		$1K Hold
7
– – ﹤0.01% 510
2018
Q2 		$1K Sell
7
-14
-67% -$1.54K ﹤0.01% 492
2018
Q1 		$2K Buy
+21
New +$2.67K ﹤0.01% 481

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Rational Advisors's UTHR Position: Q4 2020 in Review

Rational Advisors sold out of United Therapeutics (UTHR) in Q4 2020, closing a stake of 59 shares — an estimated $6K sold.

Rational Advisors first reported a position in UTHR in Q1 2018 and held it in 10 quarters. The position peaked at $19K in Q2 2019. 356 funds tracked by Wall St. Rank hold UTHR as of Q4 2020.

  • Rational Advisors reported no remaining United Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Rational Advisors sold 59 United Therapeutics shares in Q4 2020, an estimated $6K.
  • Rational Advisors first reported a position in United Therapeutics in Q1 2018 and held it in 10 quarters.
  • Rational Advisors's United Therapeutics position peaked at $19K in Q2 2019.
  • 356 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2020.

Based on Rational Advisors's 13F filing for Q4 2020, filed 5 Feb 2021.